Mark A. Velleca - Mar 18, 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Director
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Stock symbol
BDTX
Transactions as of
Mar 18, 2022
Transactions value $
$8,749
Form type
4
Date filed
3/18/2022, 04:05 PM
Previous filing
Feb 8, 2022
Next filing
Jun 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Award $8.75K +2.9K $3.02 2.9K Mar 18, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2 The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022.